Tesetaxel as First-line Therapy for Metastatic Breast Cancer
Status unconfirmed · Phase 2
Conditions studied: Breast Neoplasm
In brief
The intravenously administered taxane, paclitaxel, is one of the most commonly employed agents for the treatment of both localized and advanced breast cancer. Tesetaxel is an orally administered taxane that is in development as first- and second-line treatment for patients with advanced cancers. This study is being undertaken to determine the efficacy and safety of tesetaxel administered as first-line therapy to patients with metastatic breast cancer.
Key facts
- Study ID
- NCT01221870
- Run by
- Genta Incorporated
- People needed
- 81
- Starts
- 2010-11-01
- Expected to finish
- 2013-01-01
- Last updated by the study team
- 2012-07-24
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States (enrolling)
- The Moses H. Cone Regional Cancer Center — Greensboro, North Carolina, United States (enrolling)
- Texas Oncology - Baylor Charles A. Sammons Cancer Center — Dallas, Texas, United States (enrolling)
- The West Clinic — Memphis, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.